PFIZER INC (1985 - Present)
During the period 1985 to 1999, Mr. Goodell was retained to defend Pfizer Inc and its subsidiary in product liability suits alleging death and personal injury from the failure, or the fear of failure, of a mechanical heart valve. As a member of the national trial team, Mr. Goodell was responsible for the development of the defense strategy, development of the experts, and trial of cases. He tried a death case for three weeks, resulting in a settlement. Other responsibilities included the instruction of European counsel in defense strategy and themes, and the review and analysis of technical and regulatory documents for the defense of suits. The heart valve litigation has concluded.
In 2000, Mr. Goodell was retained to defend litigation involving the Type II diabetes drug, Rezulin, as a member of the national trial team. He tried two month-long trials involving Rezulin, the most recent resulting in a defense verdict. He also served as regional counsel to Pfizer Inc and Warner-Lambert in the Rezulin litigation. The Rezulin litigation has concluded.
In 2004, Mr. Goodell and the firm were retained as members of the national trial team and the "virtual law firm" to defend litigation involving Provera, a medication used in Hormone Replacement Therapy. He was lead counsel in the first Multidistrict Litigation trial in 2008. After Pfizer’s acquisition of Wyeth, he became a member of the national trial team for Wyeth, maker of Prempro. Mr. Goodell recently was lead counsel for a trial in West Virginia resulting in a defense verdict. This litigation is ongoing.
In 2005, Mr. Goodell and the firm were retained as members of the "virtual law firm" and as members of the national trial team in connection with the Celebrex litigation, involving claims of cardiac events as a result of the medicine. That litigation has concluded.
In 2006, Mr. Goodell and the firm were retained as members of the "virtual law firm" in connection with the Neurontin litigation, involving claims of suicide as a result of medicine. He was co-lead counsel in the first Neurontin Multidistrict Litigation trial in 2009, which plaintiffs dismissed after two days of trial. This litigation is ongoing.
Mr. Goodell and the firm were retained in 2009 as one of 20 firms in the United States in the Pfizer Legal Alliance to provide a broad range of services to Pfizer Inc. This relationship with Pfizer Inc as a PLA firm is ongoing.
BAYER CORPORATION (1987 - Present)
Mr. Goodell served as co-national trial counsel for Bayer in litigation involving hemophiliacs claiming exposure to HIV and AIDS from the use of blood factor products. He was responsible for the development and coordination of the defense of over 125 individual actions as well as a pending nationwide class action. Mr. Goodell successfully argued against certification of a statewide class action against Bayer and other defendants in New Jersey, and successfully argued to the Maryland Court of Appeals that Comment k to the Restatement of Torts, Section 402A applies to blood products in Maryland. Mr. Goodell tried a six-week case in Indianapolis involving a hemophiliac claiming infection with AIDS from blood products. That litigation has concluded.
In 1998, Mr. Goodell and the firm were retained as counsel for Bayer in litigation arising from hemophiliacs' allegations of exposure to hepatitis C from the use of blood factor products. That litigation has concluded.
In 2002, Mr. Goodell was retained for the national trial team for the drug Baycol, a statin withdrawn from the market in 2001. That litigation has concluded.
In 2002, Mr, Goodell was retained for the national trial team for PPA, an ingredient of cough and cold medicines. That litigation has concluded.
In 2004, Mr. Goodell and the firm were retained as counsel in the Cipro litigation, defending, in part, claims by postal workers exposed to anthrax who were given Cipro, and thereafter claimed injury from the Cipro. The class action was defeated and the litigation abandoned by plaintiffs.
In 2010, Mr. Goodell and the firm were retained as members of the national trial team in the Yaz litigation, involving claimed injuries from birth control pills. This litigation is ongoing. U.S.
SILICA (2003 - 2010)
Mr. Goodell and the firm were retained as a national counsel in the silica litigation to develop national strategy for the management of the litigation. They developed the national defense strategy and worked with local counsel to implement it, resulting in the dismissal of the vast majority of cases.
ASTRAZENECA (2008 - 2010)
Mr. Goodell was retained as part of the national trial team defending the medicine Seroquel against claims that it led to development of diabetes. He was also retained as trial counsel in the pain pump litigation defending against claims that a local anesthetic caused deterioration of shoulder cartilage. This litigation has concluded.
WYETH (2004 - 2007) Mr. Goodell was retained for the national trial team for diet drug litigation, and served as trial counsel. He tried one of the first cases in Philadelphia to a defense verdict. The firm managed a docket of cases in Philadelphia. That litigation has concluded.
VERMONT TALC, INC., a subsidiary of PLUESS-STAUFER INDUSTRIES, INC. (1987 - 2004)
Mr. Goodell served as national coordinating counsel in connection with 3500 product liability suits alleging lung injury from commercial talc. He was responsible for the development and implementation of coordinated defense strategy, the hiring and management of local counsel, the creation of a document repository, the review, analysis and computerization of all documentation relevant to the litigation, the coordination of discovery, and the development of medical defenses and experts. He then served as the lead trial counsel. As a result of the strategy developed, virtually all lawsuits were dismissed by plaintiffs.
TELECTRONICS PACING SYSTEMS (1995 - 2003)
Mr. Goodell and the firm were retained as national counsel for Telectronics in connection with claims arising from fractures in pacemaker leads. His representation included the development of the nationwide defense, managing Multidistrict Litigation proceedings and numerous class actions, retention of local counsel, managing individual cases throughout the United States, and serving as lead trial counsel. That litigation has concluded.
DALKON SHIELD CLAIMANTS TRUST (1991 -- 1996)Mr. Goodell was the Southeast Regional Counsel, representing the Trust in cases involving claimed injuries from the Dalkon Shield intrauterine contraceptive device. He tried several cases on behalf of the Trust in Florida and Maryland.
A. H. ROBINS CO. (1975 - 1985)
Mr. Goodell’s representation involved the defense of product liability suits alleging serious personal injuries arising out of the use of the Dalkon Shield intrauterine device. He served as a member of the national trial team for A.H. Robins with responsibility for the trial of cases in various states, development and implementation of national defense strategies, development and management of experts, and management of an active docket of 450 individual cases in Maryland. Mr. Goodell assisted Canadian counsel as both an advisor and an expert witness in a class action in Montreal. He tried several cases on behalf of A. H. Robins, one during the course of a nationally publicized withdrawal from the market, and one to a defense verdict.